1
|
Pires EM, Pugazhenthi U, Fink MK, Habenicht LM, Fong DL, Leszczynski JK, Schurr MJ, Manuel CA. Antibiotic Treatment of Corynebacterium bovis-associated Clinical Disease in NSG Mice. Comp Med 2023; 73:461-465. [PMID: 38103891 PMCID: PMC10752358 DOI: 10.30802/aalas-cm-23-000039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 09/08/2023] [Accepted: 10/10/2023] [Indexed: 12/19/2023]
Abstract
Depending on the strain of immunodeficient mice, Corynebacterium bovis infection can be asymptomatic or cause transient or prolonged skin disease. C. bovis infection of NOD. Cg- Prkdcscid Il2rgtm1Wjl /SzJ (NSG) mice results in clinical skin disease that progresses in severity. Amoxicillin metaphylaxic and prophylaxic therapy prevents transmission and infection of mice after exposure to C. bovis and inhibits the growth of C. bovis isolates at therapeutic doses that are clinically achievable in mice. Amoxicillin is not efficacious for treatment of transient clinical skin disease in athymic nude mice, but the efficacy of amoxicillin treatment has not previously been characterized in C. bovis -infected NSG mice. In the current study, NSG mice were treated with amoxicillin beginning at 5 wk after exposure to C. bovis, at which time they had well-established clinical signs of disease. Clinical signs were scored to assess disease progression, regression, and reappearance. Our results showed that amoxicillin treatment for 3 or 6 wk reduced the clinical scores of NSG mice with C. bovis -associated clinical disease. In addition, withdrawal of treatment led to the recurrence of clinical signs. Collectively, our data suggest that amoxicillin treatment is effective in alleviating the clinical signs associated with C. bovis infection for the duration of treatment in NSG mice. Clinical intervention with antibiotics for C. bovis -infected NSG mice can be an option for management of C. bovis -related clinical disease either before or during facility-wide remediation efforts.
Collapse
Affiliation(s)
| | | | | | | | - Derek L Fong
- Office of Laboratory Animal Resources
- Pathology and
| | | | - Michael J Schurr
- Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; and
| | - Christopher A Manuel
- Office of Laboratory Animal Resources
- Pathology and
- University of Colorado Cancer Center, Aurora, Colorado
| |
Collapse
|
2
|
Fagre AC, Pugazhenthi U, Cheleuitte-Nieves C, Crim MJ, Henderson KS, Fong DL, Leszczynski JK, Schurr MJ, Daniels JB, Manuel CA. Antimicrobial Susceptibility of Corynebacterium bovis Isolates from Immunodeficient Rodents. Comp Med 2021; 71:210-214. [PMID: 33836843 PMCID: PMC8223865 DOI: 10.30802/aalas-cm-20-000107] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2020] [Revised: 12/03/2020] [Accepted: 02/02/2021] [Indexed: 01/05/2023]
Abstract
Corynebacterium bovis, the causative agent of hyperkeratotic dermatitis in immunodeficient mice, is a significant problem in preclinical oncology research. Infection results in lifelong skin colonization and a decrease in successful engraftment of patient-derived xenograft tumor models. The use of antimicrobial agents for C. bovis is controversial in light of reports of poor efficacy and the possibility of selection for resistant strains. The purpose of this study was to describe the antimicrobial susceptibilities of C. bovis isolates obtained exclusively from immunodeficient rodents in order to aid in antimicrobial dose determination. Between 1995 and 2018, 15 isolates were collected from 11 research institutions across the United States. Antimicrobial susceptibility testing was performed for 24 antimicrobials commonly used against gram-positive bacteria. Our results provide an updated understanding of the susceptibility profiles of rodent C. bovis isolates, indicating little variability between geographically and temporally distant isolates. These results will facilitate appropriate antimicrobial use to prevent and treat C. bovis infections in immunodeficient rodents.
Collapse
Affiliation(s)
- Anna C Fagre
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado
| | - Uma Pugazhenthi
- Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Christopher Cheleuitte-Nieves
- Center of Comparative Medicine and Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York
| | - Marcus J Crim
- Molecular Diagnostics and Microbiology, IDEXX BioAnalytics, Columbia, Missouri
| | - Kenneth S Henderson
- Research Animal Diagnostic Services, Charles River Laboratories, Wilmington, Massachusetts
| | - Derek L Fong
- Office of Laboratory Animal Resources, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Jori K Leszczynski
- Office of Laboratory Animal Resources, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Michael J Schurr
- Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Joshua B Daniels
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado
| | - Christopher A Manuel
- Office of Laboratory Animal Resources, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; University of Colorado Cancer Center, Aurora, Colorado;,
| |
Collapse
|